The approval of ArteraAI Prostate by the FDA as a software as a medical device (SaMD) means it can now be used at the point ...

The FDA’s De Novo authorization for the tool establishes a new product code category for future AI-powered digital pathology risk-stratification tools.

The US Food and Drug Administration (FDA) has granted de novo authorisation to Artera’s ArteraAI Prostate software. This ...

Key Points Spectral Ai completed its De Novo application submission to the FDA for the DeepView System in June 2025, marking a major regulatory milestone. Revenue for the quarter declined 32.0% year ...

Abridge is looking for acquisitions after raising $700 million in 18 months. Here's what the red-hot health AI startup wants ...

Artificial intelligence is transforming healthcare — we must align government policies to support this progress. It will save ...

The American Psychological Association (APA) has called on the Federal Trade Commission to investigate “deceptive practices” ...

As agentic AI advances, it will impact patient-facing healthcare delivery models, while new questions around the ...

Oregon Health & Science University said a trained AI program can detect cancer of a larynx by picking up the distinct ...

Artificial intelligence programs can help doctors and nurses predict hours earlier which ER patients will likely require ...

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best upside stocks to invest in now. Earlier on July 23, Revolution ...

Recent news reports highlight uncertainty about pharmaceutical tariffs, an error-prone AI tool in use at the FDA, and scientific research funding in jeopardy.